WO2006115238A1 - Regulateur de la motricite gastro-intestinale - Google Patents

Regulateur de la motricite gastro-intestinale Download PDF

Info

Publication number
WO2006115238A1
WO2006115238A1 PCT/JP2006/308514 JP2006308514W WO2006115238A1 WO 2006115238 A1 WO2006115238 A1 WO 2006115238A1 JP 2006308514 W JP2006308514 W JP 2006308514W WO 2006115238 A1 WO2006115238 A1 WO 2006115238A1
Authority
WO
WIPO (PCT)
Prior art keywords
gastrointestinal motility
regulator
activation regulator
activation
motor activation
Prior art date
Application number
PCT/JP2006/308514
Other languages
English (en)
Japanese (ja)
Inventor
Tomohiko Nakata
Ryou Kanaya
Norikazu Yamaguchi
Akiyoshi Oohira
Original Assignee
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Company, Ltd. filed Critical Kowa Company, Ltd.
Priority to JP2007514704A priority Critical patent/JPWO2006115238A1/ja
Publication of WO2006115238A1 publication Critical patent/WO2006115238A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Definitions

  • the present invention relates to a gastrointestinal motility activation regulator based on a new medicinal effect of methylmethionine sulfo-um chloride (MMSC).
  • MMSC methylmethionine sulfo-um chloride
  • a decrease in the motor function of the gastrointestinal tract has been understood and recognized as a type of disease that causes various gastrointestinal disorders such as chronic gastritis, reflux esophagitis, abdominal indefinite complaints or pseudo-intestinal obstruction. It has become. Therefore, a drug containing a drug that can activate the motility function of the gastrointestinal tract can be used as a drug that can eliminate or alleviate the above gastrointestinal disorders such as chronic gastritis, that is, a gastrointestinal motility activation regulator. Has come to be recognized.
  • Non-patent Documents 1 and 2 As examples of the gastrointestinal motility activation regulator, cisapride (Non-patent Documents 1 and 2) and Nymetoku Blamide (Non-patent Documents 3 and 4) are known. It is also known that soju ( ⁇ ⁇ ), a kind of herbal medicine component, has this gastrointestinal motility activation regulating effect (Non-patent Document 5).
  • Non-patent document 1 Schuurkes, J.A.J., et al., 1985, J. Pharmacol. Exp. T., 234, 775.
  • Non-Patent Document 2 Schuurkes, J.A.J., et al., 1984, Gastrointestinal Motility, Roman, C., page 95, MTP press, Lancaster.
  • Non-Patent Document 3 Takeshi Fukuhara et al .: Nissho-Musuji, 1966, Vol. 2, No. 1, pp. 15, [PP11 038]
  • Non-Patent Document 4 Shigeaki Kumada et al .: Pharmaceutical Research, 1968, No. 39, No. 2, p. 44, [PP115 50]
  • Non-Patent Document 5 14th Revised Japanese Pharmacopoeia, 2001, D-674-677
  • An object of the present invention is to provide a new medicament having a gastrointestinal motility activation regulating action.
  • MMSC methylmethionine sulfo-chloride
  • the present invention relates to a gastrointestinal motility activation regulator containing MMSC.
  • this invention regulates activation of gastrointestinal motility, including MMSC, to suppress belching, scalding, nausea or vomiting, or to relieve chest grip, leaning, indigestion, stomach / abdominal bloating or loss of appetite Agents are also provided.
  • the gastrointestinal motility activation regulator of the present invention has a strong pharmacological action and superior effectiveness compared to the soju that is a crude drug component.
  • MMSC has not reported any side effects or other side effects of the central nervous system, such as extrapyramidal symptoms and Parkinson's symptoms, which are observed in anti-dopaminergic cisapride or methucral bramid. Therefore, a medicine containing MMSC can be used as a gastrointestinal motility activation regulator with high pharmacological action and safety.
  • MMSC is a drug that was launched in 1959.
  • MMSC has been used mainly as a gastric mucosal repair agent or for improving liver function in chronic liver disease. To date, there is no report or suggestion that it has an activity-regulating action and therefore can be a gastrointestinal motility-regulating agent.
  • the present invention provides a new application of this MMSC.
  • the MMSC used in the present invention is commercially available from, for example, Yonezawa Hamari Chemical Co., Ltd. It may be used according to the method described in Japanese Patent Publication No. 36-13209.
  • the gastrointestinal motility activation regulator of the present invention may be a single form of MMSC, or a pharmaceutically acceptable carrier or other pharmaceutical ingredient, excipient, binder, disintegrant, lubricant, It can also be used in the form of a pharmaceutical composition containing a colorant, a corrigent and the like.
  • excipients include lactose, starches, crystalline cellulose, sucrose, mannitol, light non-aqueous key acid and the like.
  • binder include hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, alpha-monoized starch, polybulurpyrrolidone, polybullic alcohol, and pullulan.
  • disintegrant include carmellose, carmellose calcium, croscarmellose sodium, crospovidone, corn starch, and low-substituted hydroxypropylcellulose.
  • lubricants include magnesium stearate and talc.
  • the colorant include tar pigments and iron sesquioxide.
  • corrigent include stevia, aspartame, and fragrances.
  • the gastrointestinal motility activation regulator of the present invention includes powders, granules, tablets, chewable tablets, film-coated tablets, dragees, drinks, soft capsules, hard capsules, jelly agents and the like depending on the purpose. It can be manufactured and used in a dosage form. In particular, it is preferable to prepare and use powders, granules, tablets, and film-coated tablets.
  • MMSC When MMSC is used as a gastrointestinal motility regulator, the dose depends on the dosage form, degree of disease, patient age, etc. MMSC is usually about 30 to 3000 mgZ for adults In particular, it is preferable to administer about 150 to 225 mgZ days.
  • the gastrointestinal motility activation regulator of the present invention has an action of improving the intestinal tract transport rate as shown in Examples described later. Therefore, the gastrointestinal motility activation regulator of the present invention can eliminate various symptoms such as chronic gastritis, reflux esophagitis, abdominal indefinite complaints or pseudo-intestinal obstruction caused by retention of intestinal contents. In addition, the present invention improves the intestinal transit rate, thereby causing retention of intestinal contents, burping, scalding, nausea, vomiting, chest gripping, leaning, indigestion, stomach / abdominal bloating and loss of appetite. It is possible to effectively suppress or eliminate symptoms such as those caused by excessive drinking or eating. Furthermore, improve intestinal transport rate and eliminate retention of intestinal contents Can also promote digestion.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un produit pharmaceutique très sûr ayant un excellent effet régulateur de la motricité gastro-intestinale. Il s'agit d'un régulateur comprenant du chlorure de méthylméthionine sulfonium, qui peut être utilisé en tant qu'excellent régulateur de la motricité gastro-intestinale avec une forte action pharmacologique sans aucun effet secondaire.
PCT/JP2006/308514 2005-04-25 2006-04-24 Regulateur de la motricite gastro-intestinale WO2006115238A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007514704A JPWO2006115238A1 (ja) 2005-04-25 2006-04-24 消化管運動賦活調整剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-127046 2005-04-25
JP2005127046 2005-04-25

Publications (1)

Publication Number Publication Date
WO2006115238A1 true WO2006115238A1 (fr) 2006-11-02

Family

ID=37214852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/308514 WO2006115238A1 (fr) 2005-04-25 2006-04-24 Regulateur de la motricite gastro-intestinale

Country Status (4)

Country Link
JP (1) JPWO2006115238A1 (fr)
KR (1) KR20080003318A (fr)
CN (1) CN101141954A (fr)
WO (1) WO2006115238A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101100901B1 (ko) * 2009-04-09 2012-01-02 주식회사 씨티네트웍스 광섬유의 어댑터 연결부위에서 광신호 유무를 확인하는 센싱 어댑터
JP2015214530A (ja) * 2013-07-31 2015-12-03 興和株式会社 胃腸薬組成物
US10509185B2 (en) 2016-04-27 2019-12-17 Huawei Technologies Co., Ltd. Optical connector with photodetector, adaptor for optical connector, and system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08259445A (ja) * 1995-01-27 1996-10-08 Takeda Chem Ind Ltd 胃排出能改善性医薬組成物
JP2000327567A (ja) * 1999-05-18 2000-11-28 Susumu Kurosawa 消化管運動改善剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08259445A (ja) * 1995-01-27 1996-10-08 Takeda Chem Ind Ltd 胃排出能改善性医薬組成物
JP2000327567A (ja) * 1999-05-18 2000-11-28 Susumu Kurosawa 消化管運動改善剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HARADA N.: "Shokaki Shikkan ni Tomonau Jikaku Shojo ni Taisuru Cabagin-U Kowa San no Yuyosei no Kento", BASIC PHARMACOLOGY & THERAPEUTICS, vol. 9, no. 12, 1981, pages 5211 - 5215, XP003006792 *
KABUSHIKI KAISHA YAKUJI NIPPOSHA: "Saikin no Shin'yaku 2002", KABUSHIKI KAISHA YAKUJI NIPPOSHA, 2002, pages 297, XP003006791 *
SALIM A.S. ET AL.: "Sulphydryl-containing agents and the prevention of duodenal ulcer relapse", PHARMACOLOGY, vol. 46, no. 5, 1993, pages 281 - 288, XP008009446 *
WATANABE T. ET AL.: "Rat Ethanol Kaiyo ni Okeru Inen'eki To Tanpakushitsu no Ryoteki Hendo ni Taisuru Methyl Methionine Sulfonium Chloride (MMSC) Mae Toyo no Koka", BASIC PHARMACOLOGY & THERAPEUTICS, vol. 22, no. 10, 1994, pages 4355 - 4361, XP003006793 *

Also Published As

Publication number Publication date
JPWO2006115238A1 (ja) 2008-12-18
KR20080003318A (ko) 2008-01-07
CN101141954A (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
TWI684583B (zh) 胱硫醚-γ-解離酶（ＣＳＥ）抑制劑（一）
TWI724332B (zh) 用於抑制磷酸鹽輸送之nhe3結合化合物及方法
TWI580427B (zh) Compositions for reducing body weight and reducing body fat, and pharmaceuticals and applications thereof
CN102112127A (zh) 用于实现减肥和治疗肥胖的逐渐增加的剂量方案
JPS61277620A (ja) 排尿困難治療剤
CN101955440B (zh) 一种阿戈美拉汀新晶型及其制备方法
WO2015010449A1 (fr) Procédé d'utilisation d'une composition de vitamine b pour favoriser la motilité du système gastro-intestinal
JP2022525202A (ja) 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量
WO2006115135A1 (fr) Agent thérapeutique pour le syndrome du côlon irritable
JP2010030963A (ja) 消化管運動賦活調整剤
JP2008056567A (ja) 胃腸疾患の治療又は予防のための医薬
WO2006115238A1 (fr) Regulateur de la motricite gastro-intestinale
WO2014056396A1 (fr) Forme cristalline du mésylate de flumatinib et son procédé de préparation et son utilisation
WO2019011350A1 (fr) Forme cristalline g de fenlean (flz), son procédé de préparation, composition la comprenant et son utilisation
WO2010022580A1 (fr) Composé médicamenteux utilisé dans le traitement de l’hyperuricémie et ses applications
CN105919967A (zh) 一种盐酸阿考替胺制剂及其应用
CN101982174A (zh) 一种镇咳平喘复方药物制剂的组方及其制备方法
CA2576926A1 (fr) Utilisation de midostaurine pour le traitement de tumeurs du stroma gastro-intestinal
CN105693805A (zh) 一种胆酸类小檗碱偶合物的制备及医药用途
KR101254511B1 (ko) 위장약 조성물
WO2017135412A1 (fr) Méthode de traitement pour les patients atteints de cancer souffrant d'insuffisance rénale grave
JP2007137896A (ja) イブプロフェン含有医薬製剤
JP4102461B2 (ja) 解熱剤
WO2017211182A1 (fr) Composition pharmaceutique pour la prévention et/ou le traitement de maladies inflammatoires
JP5822420B2 (ja) 医薬組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680008744.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020077021585

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007514704

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06745592

Country of ref document: EP

Kind code of ref document: A1